Antibacterial peptide. Stimulates angiogenesis and inhibits inflammatory responses by selectively blocking proteasome degradation of IκBα.

16-Hydroxycleroda-3,13-dien-15,16-olide, and prodigiosin are presented as candidates for autophagy inducers that can trigger cell death in a supplement or alternative medicine for cancer therapy. 16-Hydroxycleroda-3,13-dien-15,16-olide regulates the expre

KZR-504 is a selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2) (IC50s: 51 nM, 4.274 μM for LMP2 and LMP7, respectively).

2-Methoxy-5-acetoxy-furanogermacr-1(10)-en-6-one is a natural product

Enzyme-IN-1（compound 1）为基于肽的N端亲核试剂（Ntn）水解酶抑制剂，特别针对20S蛋白酶体的糜胰蛋白酶样活性（CT-L）进行抑制，可能展现出抗炎特性。

6RK73 是一种共价不可逆的特异性 UCHL1 抑制剂，IC50 为 0.23 µM。6RK73 对 UCHL3 几乎没有抑制效果 (IC50=236 µM)。6RK73 特异性抑制乳腺癌中 UCHL1 的活性。

Alogliptin-13CD3 is the deuterium-labeled Alogliptin. Alogliptin (T6192) is a selective inhibitor of DPP-4.

MyoMed-205 是一种MuRF1(肌肉环指蛋白1) 活性抑制剂。它可以防止单侧膈神经去神经12小时后引起的早期膈肌收缩功能障碍和萎缩。通过抑制MuRF1活性，MyoMed-205 减少了肌肉蛋白的泛素化和后续的蛋白酶体降解。此外，MyoMed-205 能提高磷酸化Akt(ser473)的蛋白水平，Akt对肌肉的生长和维持至关重要。MyoMed-205 适用于研究和治疗由早期失用引起的膈肌功能障碍和萎缩(DIDD)，尤其是在膈肌麻痹或机械通气等临床情况下。

LXE408 is an orally active, kinetoplastid-selective proteasome inhibitor, exhibiting non-competitive inhibitory effects. It demonstrates an IC50 of 0.04 μM for L. donovani proteasome and an EC50 of 0.04 μM for L. donovani. Moreover, LXE408 shows limited ability to traverse the blood-brain barrier. Hence, LXE408 holds promise for advancing research in the field of visceral leishmaniasis (VL).